American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
-
Lung transplantation provides very good short- and acceptable long-term survival for patients with advanced lung disease. More widespread use of marginal and distant donors can be employed in selected recipients without compromising early or late results. ⋯ The high rate of acute rejection and subsequent BOS clearly indicates that current immunosuppression strategies are inadequate. Further clinical and laboratory research into the pathogenesis of BOS will perhaps reveal new treatment options.
-
Case Reports
Rescue of acute portal vein thrombosis after liver transplantation using a cavoportal shunt at re-transplantation.
Portal vein thrombosis is a rare but devastating complication following orthotopic liver transplantation. Fulminant liver failure ensues with acute portal vein thrombosis after transplantation limiting the treatment options. ⋯ Cavoportal shunt can augment portal blood flow in adult recipients of orthotopic liver transplants. This technique can be successfully employed during re-transplantation when portal blood flow is inadequate to maintain patency.
-
Comparative Study
A cost-effectiveness analysis of biliary anastomosis with or without T-tube after orthotopic liver transplantation.
Biliary reconstruction continues to be a major source of morbidity following orthotopic liver transplantation. We wished to determine if choledochocholedochostomy without a T-tube was associated with fewer biliary complications and was less costly than choledochocholedochostomy with a T-tube. A retrospective cohort study of patients who underwent liver transplantation was performed. ⋯ Our study suggests choledochocholedochostomy without T-tube reconstruction is the preferred strategy for biliary reconstruction in orthotopic liver transplantation. It is not only associated with fewer biliary complications, but also less costly than using choledochocholedochostomy over a T-tube. Randomized prospective studies are needed to confirm our results.
-
The optimal management of Epstein-Barr virus (EBV)-induced post-transplant lymphoproliferative diseases (PTLD) remains controversial. While withdrawal or reduction of immunosuppression is widely accepted as the strategy for the treatment of EBV/PTLD, the role of additional therapeutic interventions remains less clear. Newer strategies, including anti-B-cell monoclonal antibodies and adoptive immunotherapy offer the promise of impaired efficacy and outcome against EBV disease, but lack data demonstrating how and when to use these approaches. The current review provides an overview of potential strategies and presents guidelines for the management of EBV/PTLD in solid-organ transplant recipients.